Search Results
Oct 16, 2025, 09:00 ET Mercy Offers New Hereditary Testing for High-Risk Patients
genes are transmitted, relatives have up to a 50% chance of inheriting the same problematic gene. If a patient has a mutation, many interventions are available to reduce the risk for cancer associated with the gene. Based on a patient's results, a health care provider may recommend:
More news about: Mercy
Oct 16, 2025, 08:00 ET Klotho Neurosciences CEO to Attend Longevity Biotech 2025 in Boston
(NASDAQ: KLTO) is a biogenetics company focused on the development of innovative, disease-modifying cell and gene therapies using a protein derived from a patented form of the "anti-aging" human Klotho gene (s-KL), and its novel delivery systems to transform and improve the treatment of neurodegenerative and
More news about: Klotho Neurosciences, Inc.
Oct 16, 2025, 07:00 ET Insmed to Present Multiple Analyses from Phase 3 ASPEN Study at the American College of Chest Physicians Annual Meeting 2025
therapies to treat chronic, debilitating lung diseases. The Company's early-stage programs encompass a wide range of technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Headquartered in Bridgewater,
More news about: Insmed Incorporated
Oct 15, 2025, 17:31 ET Gastrointestinal Neuroendocrine Tumors Market Set to Surge by 2034 Amidst Advancements in Treatment Options | DelveInsight
modulators, such as CAM2029 and RYZ101, aim to enhance targeting and tolerability. Concurrent advances in diagnostic technologies, including gene expression assays such as the NETest and circulating tumor biomarkers, offer potential for earlier detection and real-time monitoring of disease. Collectively,
More news about: DelveInsight Business Research, LLP
Oct 15, 2025, 14:37 ET Women are more vulnerable to brain diseases - New UCLA research explains why and points to promising treatment
Science Translational Medicine, Dr. Voskuhl and her team discovered that a gene on the X chromosome (Kdm6a) triggers heightened inflammation in women's brains. Since women carry two X chromosomes, this gene's double activity can
More news about: CleopatraRX
Oct 15, 2025, 14:30 ET Nabsys Highlights OhmX™ Platform's Ability to Accurately Verify Structural Variants in Undiagnosed Disorders and Workflow Optimizations at American Society of Human Genetics (ASHG) 2025 Annual Meeting
technology at a tertiary children's hospital and how the OhmX Platform works in symphony with a comprehensive multi-omics strategy to accelerate rare disease gene discovery. Catherine Brownstein, M.P.H., Ph.D., Boston Children's Hospital remarked, "Nabsys' EGM technology, which delivers
More news about: Nabsys
Oct 15, 2025, 10:35 ET GTCR Announces $200 Million Strategic Minority Investment in Solmetex
healthcare and industrial technology investments spanning Europe, Asia, and the United States. GTCR looks forward to working alongside Solmetex CEO Gene Dorff, an experienced dental industry professional with more than two decades of sector expertise, and the Company's management team to drive continued
More news about: GTCR
Oct 15, 2025, 10:30 ET Life Science Logistics Market is expected to generate a revenue of USD 236.28 Billion by 2032, Globally, at 8% CAGR: Verified Market Research®
must evolve to ensure secure handling and distribution. The rise of mRNA vaccines, cell and gene therapies, and specialty drugs has amplified the need for precision cold chain management. Logistics providers are investing
More news about: Verified Market Research
Oct 15, 2025, 09:15 ET Illumina constellation mapped read technology uncovers hard-to-see genomic insights in GeneDx pilot
expansions; SMN1, which is associated with spinal muscular atrophy but is difficult to detect based on the highly homologous SMN2 gene; NCF1, which is associated with an inherited immune disorder called chronic granulomatous disease, but is challenging to identify
More news about: Illumina, Inc.
Oct 15, 2025, 09:03 ET Deck Bio and ReTrax Therapeutics Awarded 2025 Bristol Myers Squibb Golden Tickets
a single drug, leading to higher response rates and reduced drug resistance. ReTraX Therapeutics is developing a one-time AAV gene therapy that upregulates FAN1, a DNA-repair enzyme that stabilizes pathogenic repeat expansions, delivering a durable, disease-modifying approach for
More news about: LabCentral
Oct 15, 2025, 08:45 ET Cellular Immunotherapy Breakthroughs Fuel $370 Billion Market Surge
"We chose InspiroGene by McKesson to pioneer the Amtagvi specialty pharmacy option due to their offerings and commitment to cell and gene therapy patient access," said Dan Kirby, Chief Commercial Officer at Iovance Biotherapeutics. "We believe that InspiroGene will play a
More news about: Equity Insider
Oct 15, 2025, 08:42 ET STEMup™ and Allegheny Health Network Partner to Advance STEM Workforce Development at AHN Suburban
The two programs are being funded through generous grant support, and will prioritize relationships with companies that are developing gene and cell therapies, as well as healthcare artificial intelligence solutions. "Partnering with STEMup is a natural extension of
More news about: STEMup Science and Technology Foundation
Oct 15, 2025, 07:05 ET REGENXBIO to Participate in Upcoming Investor Conferences
REGENXBIO is a biotechnology company on a mission to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the field of AAV gene therapy. REGENXBIO is advancing a late-stage pipeline of one-time treatments for rare and retinal diseases,
More news about: REGENXBIO Inc.
Oct 15, 2025, 07:00 ET Plasmidsaurus Launches Ultrafast RNA-Seq Service, Transforming Gene Expression Analysis with Unprecedented Speed, Affordability, and Convenience
service to Illumina short read applications, Plasmidsaurus is bringing the same speed, convenience, and insights they pioneered for plasmid sequencing to gene expression analysis. Attendees at this week's American Society of Human Genetics (ASHG) 2025 Annual Meeting can meet with Plasmidsaurus scientists
More news about: Plasmidsaurus
Oct 15, 2025, 07:00 ET Origin Agritech Executes Northeast China Market Re-Entry with Product Showcase and Technology Seminar
Origin's transgenic technology platform, highlighting the advancement of the BBL2-2 event. China Agricultural University Professor Feng Tian presented gene editing applications developed in collaboration with Origin, demonstrating the Company's continued innovation in biotechnology solutions.
More news about: Origin Agritech Limited
Oct 15, 2025, 07:00 ET Insmed to Host Third-Quarter 2025 Financial Results Conference Call on Thursday, October 30, 2025
approved to treat chronic, debilitating lung diseases. The Company's early-stage programs encompass a wide range of technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Headquartered in Bridgewater,
More news about: Insmed Incorporated
Oct 15, 2025, 06:00 ET Global Wellness Summit Unveils Packed 3-Day Agenda for 2025 Conference in Dubai, November 18-21
MD, president of Gladstone Institutes in San Francisco, will explain how medicine is entering a dramatic new age of cures—where breakthroughs in gene editing and biomedical science are poised to eliminate once-incurable diseases like cancer, Alzheimer's, and heart disease.
More news about: Global Wellness Summit
Oct 15, 2025, 04:04 ET Indiens Institut Nr. 1, IIT Madras, und eine dänische Universität entdecken genetische „Schalter", die die Krankheitsforschung revolutionieren könnten
diese Gen-Gen-Interaktionen den Stoffwechsel dynamisch neu vernetzen, liefert die Studie einen wichtigen Baustein für die Entschlüsselung, wie mehrere Gene zusammenwirken, um komplexe Phänotypen zu modifizieren und zu verbessern. Die Studie wurde von Herrn Srijith Sasikumar, einem
More news about: IIT Madras
Oct 15, 2025, 02:00 ET La vidéo "Diabète & Préjugés » développée par Abbott révèle que les idées reçues peuvent avoir un impact sur la prise en charge des personnes vivant avec un diabète.
blagues. La honte mène au silence : Près d'une personne vivant avec un diabète sur 4 a choisi, par gêne ou par inquiétude, de ne pas parler de son diagnostic à sa famille ou à ses amis1. Des
More news about: Abbott
Oct 14, 2025, 10:30 ET FV Recycling Acquires Mid America Paper Recycling, Expanding National Presence and Service Capabilities
represents a transformative step forward for FV Recycling as we expand our ability to serve customers with comprehensive recycling solutions," said Gene Smith, President of FV Recycling. "Mid America's deep-rooted supplier relationships and decades of industry experience perfectly complement our transportation
More news about: FV Recycling
Oct 14, 2025, 09:00 ET Grow Therapy Names New Leaders in Marketing, Data & Design to Power Next Chapter
accelerate its rapid growth and innovation: Marshall Ball joins as Senior Vice President of Marketing, reporting to CEO and Co-founder Jake Cooper. Gene Tabach is appointed Vice President of Data, and Evie Alexander will lead as Vice President of Design. Both will report to CTO and Co-founder Alan Ni.
More news about: Grow Therapy
Oct 14, 2025, 09:00 ET Lunit AI Predicts Immunotherapy Outcome in Colorectal, Kidney, and Lung Cancer at ESMO 2025
with non-inflamed tumors. No such benefit was observed in the SUN arm. Findings were validated in an independent ccRCC cohort and aligned with inflamed gene expression signatures from The Cancer Genome Atlas, supporting AI-based immune phenotyping as a promising biomarker to guide treatment selection between
More news about: Lunit
Oct 14, 2025, 09:00 ET Complete Genomics Highlights New Products, Partnerships, First DNBSEQ User Group Meeting at ASHG 2025
CoLab Presentation (Oct. 15, 10:15 a.m., Theater 2, Exhibit Hall): Corbin Jones (UNC Chapel Hill) will share early insights into spatial gene expression in microscopic colitis using Stereo-seq. Industry Workshop (Oct. 16, 3:00 p.m., Room 204AB): Stanford's Michael
More news about: Complete Genomics
Oct 14, 2025, 08:30 ET Optimized Conjugation Solution for Precise Extrahepatic Delivery of Small Nucleic Acid Drug, Upcoming Webinar Hosted by Xtalks
introduce technical solutions and application cases for small RNA drug conjugation, focusing on conjugate product identification, precise delivery and gene silencing, as well as differences across methods, offering new insights to boost research efficiency. The topics that will be
More news about: Xtalks
Oct 14, 2025, 08:10 ET Trinity Capital Inc. Provides $130 Million in Growth Capital to Candel Therapeutics, Supporting Development of Viral Immunotherapies to Fight Cancer
established two clinical-stage multimodal biological immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) gene constructs, respectively. CAN-2409 is the lead product candidate from the adenovirus platform. The Company recently completed successful phase 2a clinical
More news about: Trinity Capital Inc.